Shire PLC said a U.S. district court ruled that Abhai LLC infringed on the Dublin-based drugmaker's patents related to the extended-release version of its attention deficit hyperactivity disorder drug Adderall.
The U.S. District Court of the District of Massachusetts passed the ruling after Shire sued Abhai regarding its abbreviated new drug application to market a generic version of Adderall XR.
The ruling prohibits Abhai from marketing its generic copy until the original patents expire. Further, the court sanctioned Abhai for "litigation misconduct."
The amount Abhai will pay Shire will be decided at a later date.